PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS, October 10, 2025--(BUSINESS WIRE)--Regulatory News: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), ...

Please provide your email address to receive an email when new articles are posted on . NDS-ECNW has obtained a U.S. patent for its Trimoxi injectable formulation for prophylaxis after cataract ...

BRIDGEWATER, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of risperidone ...

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the publication of efficacy ...

Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound) will provide new options for the availability of Albumin-Bound Paclitaxel to treat patients with certain types of cancer ...

The FINANCIAL — AstraZeneca on October 23 announced that the US Food and Drug Administration (FDA) has approved Bydureon BCise (exenatide extended-release) injectable suspension, a new formulation of ...

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Lundbeck announced today that the U.S. Food and Drug Administration (FDA) ...

Meitheal, through parent company Hong Kong King-Friend, launches generic paclitaxel Protein-bound paclitaxel formulation is used to treat various types of cancer, including metastatic breast cancer ...

UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults. 1 This approval marks a ...

FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I ...